Abstract
Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.
| Original language | English |
|---|---|
| Pages (from-to) | 621-629 |
| Number of pages | 9 |
| Journal | Hepatology Research |
| Volume | 43 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Infectious Diseases
Cite this
Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. / Ikegami, Toru; Shirabe, Ken; Fukuhara, Takasuke; Furusyo, Norihiro; Kotoh, Kazuhiro; Kato, Masaki; Shimoda, Shinji; Aishima, Shinichi; Soejima, Yuji; Yoshizumi, Tomoharu; Maehara, Yoshihiko.
In: Hepatology Research, Vol. 43, No. 6, 06.2013, p. 621-629.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation
AU - Ikegami, Toru
AU - Shirabe, Ken
AU - Fukuhara, Takasuke
AU - Furusyo, Norihiro
AU - Kotoh, Kazuhiro
AU - Kato, Masaki
AU - Shimoda, Shinji
AU - Aishima, Shinichi
AU - Soejima, Yuji
AU - Yoshizumi, Tomoharu
AU - Maehara, Yoshihiko
PY - 2013/6
Y1 - 2013/6
N2 - Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.
AB - Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.
UR - http://www.scopus.com/inward/record.url?scp=84878800040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878800040&partnerID=8YFLogxK
U2 - 10.1111/hepr.12003
DO - 10.1111/hepr.12003
M3 - Article
VL - 43
SP - 621
EP - 629
JO - Hepatology Research
JF - Hepatology Research
SN - 1386-6346
IS - 6
ER -